News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

Filter by:

All News Press Releases Events

08.09.2024

Innoviva Specialty Therapeutics’ Pathogen-Targeted Antibiotic XACDURO® is Nominated for the 2024 Prix Galien USA Best Biotechnology Product Award

Read More

07.01.2024

Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Read More

05.20.2024

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Read More

04.24.2024

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Read More

02.05.2024

Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer

Read More

01.04.2024

Matt Ronsheim Appointed President of Innoviva Specialty Therapeutics

Read More

11.01.2023

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Read More

10.11.2023

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Read More

09.18.2023

XACDURO, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Read More

05.23.2023

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

Read More